Design win; STM32 MCU runs wearable cardiac recorder

October 20, 2015 // By Graham Prophet
An STM32 microcontroller from STMicroelectronics, performs key functions inside HTEC’s wearable ECG recorder that provides continuous and accurate remote cardiac monitoring.

HTEC (Belgrade, Serbia) is a private R&D centre that provides engineering services for international customers. HTEC has developed its Tele-Health system as an in-house project managed by an HTEC spin-off company HUMEDS (

Different types of cardiac arrhythmia, or irregular heartbeat, affect millions of people of all ages worldwide. With the accurate and timely diagnosis, causes of many arrhythmias can be effectively treated. Unlike the more common ambulatory heart-rate monitor that is downloaded each day, for the doctor to inspect a patient’s heart rate over the past 24 hours, the STM32-equiped 3-lead ECG recorder is at the patients’ disposal any place and any time to record the data. The moment the patient has concerns, they simply apply the recorder to their chest to instantly record and send the essential cardiac data to the physician, over HTEC’s cloud-based telemedicine solution, so the doctor can use the data to detect and diagnose arrhythmia.

The cardiac device uses dry electrodes that easily apply to the patient’s skin. The STM32 F4 chip’s computing capabilities play a vital role in analysing the complex ECG signal coming from the electrodes and in converting it into medically useful information. Extensively tested against the MIT ECG databases, HTEC’s advanced signal-filtering algorithms have shown excellent results [Ref. 1]. The low-power microcontroller’s dynamic power scaling has enabled HTEC developers to optimise the application’s energy use so it can record continuously for seven days without re-charging.

Srdjan Jovanovic, CTO, HTEC observes, “The superior processing power and energy efficiency of ST’s control chip have helped us develop a consumer device with medical-grade quality that can make a big difference to people with heart problems both known and hidden.”

Clinical trials are starting now with the new cardiac recorder potentially available in the market by the end of 2015, upon the release of product certification in Europe (CE) and China (CFDA). Availability in other markets is dependent on the